Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

In this multicenter, single‐arm, phase II study, the efficacy and safety of ibrutinib were examined in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL). Patients (age ≥20 years) with relapsed or refractory MCL who had progressed after receiving at least one prior treatment re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Maruyama, Dai, Nagai, Hirokazu, Fukuhara, Noriko, Kitano, Toshiyuki, Ishikawa, Takayuki, Shibayama, Hirohiko, Choi, Ilseung, Hatake, Kiyohiko, Uchida, Toshiki, Nishikori, Momoko, Kinoshita, Tomohiro, Matsuno, Yoshihiro, Nishikawa, Tomoaki, Takahara, Satoko, Tobinai, Kensei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198949/
https://ncbi.nlm.nih.gov/pubmed/27616553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13076
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky